FDA panels to review bone drug safety - FiercePharma
Links shared publicly online about this topic.
- 18total visits
FDA panels to review bone drug safety - FiercePharma
View full resource at fiercepharma.com
Tags: Bone, Osteoporosis Medication, Drug, FDA, Fosamax, Boniva, Safety
Most Recently Shared on September 6, 2011 at 4:03 pm By:
FDA panels gear up for bone-drug safety review. Should Fosamax, Boniva, et al, be limited to 5 years? http://t.co/PglkphC $MRK $ROG
Weight loss pill Qnexa wins panel vote and awaits approval
news-medical.net — “The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.” View full resource at news-medical.net
Most Recently Shared on April 5, 2012 at 11:08 pm By:
Diet News: Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the ... http://t.co/rGbONdEq
FDA says Merck's ridaforolimus meets study goal - Yahoo! News Canada
ca.news.yahoo.com — “From Yahoo! News Canada: WASHINGTON (Reuters) - Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic soft tissue or bone sarcoma, U.S. health regulators said on Friday. A staff review document released by the Food and Drug Administration also said the treatment known by the brand name Taltorvic showed no new or unexpected safety signals in clinical research. The drug will come before an ” View full resource at ca.news.yahoo.com
Most Recently Shared on March 16, 2012 at 6:23 pm By:
Bruce Shriver PhD, Doctor, Health Advocate, and Patient Advocate
FDA says Merck's ridaforolimus meets study goal with sarcoma http://t.co/gK8t8tL4
FDA says Merck's ridaforolimus meets study goal - Yahoo! News
news.yahoo.com — “From Yahoo! News: WASHINGTON (Reuters) - Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic soft tissue or bone sarcoma, U.S. health regulators said on Friday. A staff review document released by the Food and Drug Administration also said the treatment known by the brand name Taltorvic showed no new or unexpected safety signals in clinical research. The drug will come before an advisor” View full resource at news.yahoo.com
Most Recently Shared on March 16, 2012 at 2:46 pm By:
HealthTrendster Health Executive
FDA says Merck's ridaforolimus meets study goal - WASHINGTON (Reuters) - Merck & Co Inc's ridaforolimus tablets met ... http://t.co/olPZGSSo
FDA says Merck's ridaforolimus meets study goal - Yahoo! News
news.yahoo.com — “From Yahoo! News: WASHINGTON (Reuters) - Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic soft tissue or bone sarcoma, U.S. health regulators said on Friday. A staff review document released by the Food and Drug Administration also said the treatment known by the brand name Taltorvic showed no new or unexpected safety signals in clinical research. The drug will come before an advisor” View full resource at news.yahoo.com
Most Recently Shared on March 16, 2012 at 2:45 pm By:
FDA says Merck's ridaforolimus meets study goal: WASHINGTON (Reuters) - Merck & Co Inc's ridaforolimus tablets m... http://t.co/y7DvS2Cd
FDA panel supports continued testing of pain drugs - seattlepi.com
seattlepi.com — “WASHINGTON (AP) — A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions. Drugmakers have touted the drugs, known as nerve growth factor inhibitors, as a potential breakthrou” View full resource at seattlepi.com
Most Recently Shared on March 15, 2012 at 9:22 pm By:
Drugs and Devices OW OW Health
FDA panel supports continued testing of pain drugs: FDA panel supports continued testing of pain drugs Associate... http://t.co/hdzk5XlI
Arthritis Drugs Linked To Bone Decay Should Continue To Be Tested: FDA Panel
huffingtonpost.com — “WASHINGTON — A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions.” View full resource at huffingtonpost.com
Most Recently Shared on March 13, 2012 at 8:37 am By:
Arthritis Drugs Linked To Bone Decay Should Continue To Be ... http://t.co/mS64xHvF
Arthritis Drugs Linked To Bone Decay Should Continue To Be Tested: FDA Panel
huffingtonpost.com — “WASHINGTON — A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions.” View full resource at huffingtonpost.com
Most Recently Shared on March 13, 2012 at 4:55 am By:
Arthritis OW OW Health and Active Health Library
Arthritis Drugs Linked To Bone Decay Should Continue To Be Tested: FDA Panel: The Food and Drug Administration's... http://t.co/DebKIEN5
FDA Panel Supports Continued Testing Of Pain Drugs | ThirdAge
thirdage.com — “ A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure. The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions. Reports of joint failure led the agency to halt studies of the drugs in 2010 before any of the medications” View full resource at thirdage.com
Most Recently Shared on March 13, 2012 at 2:04 am By:
FDA Panel Supports Continued Testing Of Pain Drugs http://t.co/4Bg00Va6
Arthritis Drugs Linked To Bone Decay Should Continue To Be Tested: FDA Panel
huffingtonpost.com — “WASHINGTON — A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions.” View full resource at huffingtonpost.com
Most Recently Shared on March 12, 2012 at 10:46 pm By:
Arthritis Drugs Linked To Bone Decay Should Continue To Be Tested: FDA Panel http://t.co/vgMzynVE
UCLA Professor Says Qnexa Has The "Highest Efficacy" for Weight Loss
emaxhealth.com — “After a second review of its effectiveness and safety profile, Qnexa, an anti-obesity drug by Vivus Inc, has gained an FDA panel's approval and may so...” View full resource at emaxhealth.com
Most Recently Shared on February 23, 2012 at 5:05 pm By:
Denise Reynolds RD Dietitian and Nutritionist
UCLA Professor on FDA Panel Says Qnexa Has The "Highest Efficacy" for Weight Loss http://t.co/tCgqYnQr
UPDATE 2-US FDA staff focus on safety of Forest lung drug | Reuters
reuters.com — “* Drug worked to treat chronic lung disease-FDA staff* Uncertain signals about heart safety with drug* FDA advisory panel to review drug on ThursdayBy Anna YukhananovWASHINGTON, Feb 21 (Reuters) -” View full resource at reuters.com
Most Recently Shared on February 21, 2012 at 2:24 pm By:
RT @JohnCFierce: FDA regulators like Forest COPD drug's efficacy, but raise questions on cardio risks for the class. http://t.co/qxyBK25k
FDA notes concerns about Vivus diet pill safety ahead of panel - FierceBiotech
fiercebiotech.com — “U.S. regulators have cited concerns about the safety of Vivus’ ($VVUS) experimental diet pill Qnexa in review documents as the California drug developer pursues the first FDA approval of a Read more...” View full resource at fiercebiotech.com
Most Recently Shared on February 17, 2012 at 3:52 pm By:
FDA notes concerns about Vivus diet pill safety ahead of panel http://t.co/Z8Nc7jXR $VVUS
Senators propose relaxing FDA conflict rules | Reuters
reuters.com — “WASHINGTON (Reuters) - A bill that would loosen conflict of interest rules for advisers to the Food and Drug Administration has been proposed by three U.S. senators seeking to speed up review times for” View full resource at reuters.com
Most Recently Shared on October 14, 2011 at 4:54 pm By:
Bill allowing drug company experts to sit on FDA panels will compromise drug and medical device safety http://t.co/cFOgrwq9 @AnnaHealth
FDA advisory panel suggests warning for bisphosphonates but does not specify wording
news-medical.net — “Two independent advisory panels to the Food and Drug Administration (FDA) on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States. They did not however mention the exact words of the safety warnings and did not recommend limiting use of the drugs to a proposed five years. About 11 percent of women 55 and older take the drugs to prevent bone fractures.” View full resource at news-medical.net
Most Recently Shared on September 12, 2011 at 3:09 pm By:
Osteoporosis News: FDA advisory panel suggests warning for bisphosphonates but does not specify wording: Two ind... http://t.co/pV4RZTU
Bisphosphonates - New Labeling Data On Long-term Usage Recommended By FDA Advisory Panel - QualityPoint Technologies
qualitypointtech.net — “Bisphosphonates, medications for the treatment and prevention of osteoporosis and other bone conditions, should have additional data on their labels on treatment duration, an FDA Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee (the Panel) recommended. However, the panel did not go as far as advising that specific time limits be included. Approximately 5 million Americans fill bisphosphonates prescriptions annually, and include such bran” View full resource at qualitypointtech.net
Most Recently Shared on September 10, 2011 at 8:45 pm By:
Bisphosphonates - New Labeling Data On Long-term Usage Recommended By FDA Advisory Panel: Bisphosphonates, medicat... http://t.co/07wDoRQ
Advertisement
